Quantifying the Benefits of Digital Biomarkers in Pharma

This session is an invite-only meeting. To find out more please contact us.

With the rise of connected sensor technologies, and wearable devices that can offer objective, continuous patient measurements, healthcare stakeholders are presented with a wealth of opportunities to innovate how we measure health. In particular, digital biomarkers have emerged as potential game-changers within drug development. Yet, the journey to their full-scale implementation is challenging and pharma has but cautiously adopted digital biomarkers in R&D.

Join this roundtable to discuss how we can surmount the current scepticism surrounding digital endpoints, including digital biomarkers. With your peers you’ll tackle the following questions:

• What are the proof points pharma requires to deploy digital biomarkers and endpoints with greater confidence?

• What are the quantifiable benefits of leveraging technology-enabled measurements in drug development? Who is leading the charge?

• What are the greatest barriers to adoption of technology-enabled measurements and how can we as an industry come together to overcome the biggest obstacles?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.